(Hypertension. 1999;33:207-211.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Angiotensin-(1–7) Reduces Smooth Muscle Growth After Vascular Injury
From The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.
Correspondence to E. Ann Tallant, The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1032. E-mail atallant{at}wfubmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Regulation of vascular smooth muscle cell growth is critical to the maintenance of normal blood flow and vessel patency. Angiotensin-(1–7) [Ang-(1–7)] inhibits proliferation of vascular smooth muscle cells in vitro and opposes the mitogenic effects of angiotensin II. The present study investigated whether Ang-(1–7) inhibits vascular smooth muscle cell growth in vivo by determining its effect on neointimal formation and medial remodeling in balloon-injured carotid arteries. The carotid arteries of adult male Sprague-Dawley rats were injured with a balloon embolectomy catheter. Ang-(1–7) in saline (24 µg/kg per hour) or saline alone was infused intravenously for 12 days after injury. Pumps containing bromodeoxyuridine were implanted at the same time to determine DNA synthesis. Intravenous infusion increased plasma Ang-(1–7) to 166.0±41.2 fmol/mL (n=6) compared with 46.9±4.2 fmol/mL (n=8) in saline-infused rats. Plasma concentrations of Ang II were not changed by Ang-(1–7) infusion. Elevation in circulating Ang-(1–7) had no effect on either blood pressure or heart rate compared with saline controls. Histomorphometric analysis of carotid arteries indicated that Ang-(1–7) infusion significantly reduced neointimal area compared with rats infused with saline (0.063±0.011 versus 0.100±0.009 mm2; P<0.05). In contrast, Ang-(1–7) infusion had no effect on medial area of the injured or the contralateral uninjured artery compared with saline controls. Ang-(1–7) infusion also reduced the rate of DNA synthesis in both the neointima and the media of the injured vessels. Therefore, exogenous Ang-(1–7) inhibited vascular smooth muscle cell proliferation associated with balloon-catheter injury. Similar increases in endogenous plasma Ang-(1–7) and inhibition of neointimal growth were observed in rats after angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist administration, suggesting that Ang-(1–7) may contribute to the in vivo antiproliferative effects of these agents on vascular smooth muscle.
Key Words: angiotensin • angiotensin II • muscle, smooth • vascular injury • vascular proliferation • hyperplasia
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin-(1–7) [Ang-(1–7)] is a biologically active member of the renin-angiotensin peptide family (as recently reviewed1 ). Ang-(1–7) is derived from angiotensin I (Ang I) and angiotensin II (Ang II) by endogenous tissue peptidases2 and is present in tissues and plasma at concentrations similar to Ang II.3 4 5 Plasma Ang-(1–7) is elevated after treatment of animals or humans with angiotensin-converting enzyme (ACE) inhibitors that reduce Ang II production or angiotensin type 1 (AT1) receptor antagonists that block Ang II–mediated events.3 4 5 The first recognized responses to Ang-(1–7) were the stimulation of vasopressin release from neuropeptidergic neurons6 and the release of prostaglandins,7 8 9 10 effects also produced by Ang II. However, subsequent studies showed that Ang-(1–7) is devoid of the vasoconstrictor, central pressor, and thirst-stimulating actions of Ang II. In fact, new findings suggest that Ang-(1–7) opposes many of the known actions of Ang II.1
Although Ang II is a potent vasoconstrictor, recent results suggest that Ang-(1–7) regulates arterial pressure by counteracting the pressor effects of Ang II. Ang-(1–7) reduced the blood pressure of spontaneously hypertensive rats11 and renovascular hypertensive dogs,12 while central neutralization of Ang-(1–7) with a selective antibody increased the blood pressure of rats.13 The heptapeptide relaxed canine coronary artery rings through the release of nitric oxide, bradykinin, or both.14 Ang-(1–7) released vasorelaxant prostacyclin from cultured vascular cells,7 8 9 while indomethacin abolished the vasodilator effects of Ang-(1–7) in pithed rats15 and piglet pial arterioles.16 Recent studies by Iyer et al17 18 in spontaneously hypertensive rats chronically treated with both an ACE inhibitor and an AT1 receptor antagonist showed a rapid pressor response to administration of a monoclonal antibody to Ang-(1–7), a neprilysin inhibitor, or the nonselective angiotensin peptide antagonist [sarcosine1-threonine8]angiotensin II ([Sar1-Thr8]Ang II). Because these agents effectively reduced circulating Ang-(1–7) or inhibited its activity, the endogenous depressor action of Ang-(1–7) was unmasked. Taken together, these results suggest that Ang-(1–7) opposes the pressor effects of Ang II.
Ang-(1–7) also opposes the mitogenic response to Ang II in cultured vascular smooth muscle cells (VSMC). We showed that Ang-(1–7) inhibited the serum-, Ang II–, or platelet-derived growth factor–stimulated growth of cultured VSMC,19 in contrast to the growth-stimulatory effects of Ang II.20 21 Ang-(1–7) caused a dose-dependent inhibition of [3H]thymidine incorporation into serum-stimulated VSMC as well as a decrease in cell number. Therefore, we examined the effect of exogenous Ang-(1–7) on neointimal formation and medial remodeling in balloon-injured carotid arteries to determine whether Ang-(1–7) also attenuated stimulated vascular growth in vivo.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
Twelve- to 14-week-old male Sprague-Dawley rats (body weight, 300 to 400 g), derived from founder animals acquired from the Zentralinstitut für Versuchstierkunde, Hannover, Germany, were bred and raised at the American Association for Accreditation of Laboratory Animal Care–accredited animal facility of Wake Forest University School of Medicine. All animals were provided normal rat chow (Prolab R-M-L 3000 containing 0.44% sodium, Purina Mills, Inc) and tap water ad libitum and were housed in individual cages with a 12-hour dark/light cycle.
Experimental Protocol
Rats were randomly divided into 2 groups of 6 to 8 rats each.
Each rat was anesthetized with an intramuscular injection of
ketamine hydrochloride (40 mg/kg; Ketaset, Fort Dodge
Laboratories, Inc), xylazine (4 mg/kg; Rompun, Miles), and
acepromazine maleate (0.5 mg/kg; PromAce, Fort Dodge Laboratories,
Inc). An osmotic minipump (model 2ML2, Alzet osmotic pump, Alza)
implanted subcutaneously delivered via catheter either 24 µg/kg per
hour of Ang-(1–7) (Bachem) in saline or saline alone (5 µL/h) into
the jugular vein. A second subcutaneous minipump delivered the
nonradioactive thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) (0.8
mg/kg per day in saline, 5 µL/h; Boehringer Mannheim).
In anesthetized animals implanted with osmotic pumps for drug administration, the left common carotid artery wall was injured with an embolectomy balloon catheter (2F Fogarty, Baxter Healthcare) to induce neointimal formation, as described by Clowes et al.22 The left and right carotid bifurcations and external carotid branches were exposed by an incision through the skin of the ventral neck. After ligation of the external carotid artery, the embolectomy catheter was introduced into the left common carotid artery and passed to the aorta. Endothelial denudation and artery wall injury were achieved by simultaneously withdrawing and twisting the catheter through the common carotid while the catheter balloon was inflated with 0.1 mL 0.9% NaCl. This process was repeated 3 times before removal of the catheter and ligation of the external carotid artery. The right carotid bifurcation was similarly exposed as a sham-operated control, and the right external carotid artery was ligated before wound closure.
After 12 days of peptide infusion, the rats were anesthetized with the combination of ketamine, xylazine, and acepromazine. Blood pressure and heart rate were measured on a multichannel polygraph (model 2000, Gould) by insertion of an 18-gauge angiocatheter (Baxter Healthcare) into the abdominal aorta and attachment of the catheter to a strain gauge transducer (Spectramed TXXAD-R, Spectramed). Blood (7 mL) was withdrawn for angiotensin peptide measurement, as described below. A 5% solution of Evans blue dye (0.3 mL) was administered via the catheter to identify denuded and injured artery, followed by a bolus injection of pentobarbital sodium (25 mg/kg). The arteries were perfusion-fixed in situ through the catheter at a pressure of 110 mm Hg with 4% phosphate-buffered formalin after flushing with warm, heparinized (2 U/mL) PBS. Four 5.0-mm consecutive samples from the blue-stained region of the left carotid artery and a corresponding region of the right carotid artery were removed, placed overnight in 4% PBS, and embedded in paraffin.
Paraffin-embedded sections (4 µm thick) were mounted on glass slides and stained with hematoxylin and eosin. Cross-sectional areas (3 to 4 per vessel) were measured by morphometry, using a computerized imaging system (MCID, Imaging Research, Inc) calibrated for distance (millimeters) and area (square millimeters) before each analysis. The media was defined as the area circumscribed by the internal and external elastic laminae. The neointima was defined as the area delimited by the internal elastic lamina and the lumen–artery wall interface.
Replication of VSMC was determined with the use of an indirect peroxidase-labeled antibody technique to detect the BrdU that was incorporated into cell nuclei during the S phase of DNA synthesis. Artery sections were deparaffinized, and endogenous peroxidase activity was blocked with H2O2 (0.3% in methanol). Sections were digested with 0.1 mg/mL pepsin in 0.1N HCl for 60 minutes. The DNA was denatured and stabilized by immersion in 1.5N HCl for 30 minutes at 37°C followed by rinsing in 0.1 mol/L Na-tetraborate, pH 8.5. After they were rinsed in PBS, sections were incubated with a monoclonal mouse antibody to BrdU (1:10; Boehringer-Mannheim) overnight at 4°C, followed by a biotinylated horse anti-mouse IgG (1:400; Vector Laboratories) for 3 hours at 4°C and an avidin:biotin peroxidase complex (1:50, Standard Vectastain Elite ABC kit, Vector) for 30 minutes at 22°C. The peroxidase reaction was visualized with 0.1% 3,3'-diaminobenzidine tetrachloride. Cell nuclei were counterstained with hematoxylin. The numbers of hematoxylin-stained and BrdU-positive nuclei from 3 to 4 cross-sections per artery per animal were counted within 0.005-mm2 areas of the neointima and media at x400 magnification by a single investigator blinded to the animal treatment. The BrdU labeling index was calculated as the number of peroxidase-positive nuclei/total number of nucleix100.
Angiotensin Peptide Assays
Blood was collected into chilled tubes containing 25
mmol/L EDTA and a cocktail of peptidase inhibitors
(0.44 mmol/L o-phenanthroline, 0.12 mmol/L
pepstatin A, and 1 mmol/L 4-chloromercuribenzoic acid). Blood
samples were stored on ice before processing. Blood cells were
collected by centrifugation at 4°C, and the plasma
was stored at –20°C. Immunoreactive plasma levels of Ang II and
Ang-(1–7) were measured by radioimmunoassay, as previously
described.3 4 The minimum detectable levels for the
Ang II and Ang-(1–7) assays were 4.0 and 2.2 fmol per tube,
respectively.
Statistical Analysis
All data are presented as mean±SEM. Statistical
differences were evaluated by 1-way ANOVA followed by Dunnett's post
hoc test with a criterion set for statistical significance of
P<0.05. Student's t test was used when
comparisons were made between 2 groups only. Nonparametric
analysis with the use of the Mann-Whitney test was performed
when the SDs of the 2 groups were significantly different when assessed
by parametric analysis.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effect of Intravenous Infusion of Ang-(1–7) on Blood Pressure, Heart Rate, and Angiotensin Peptides
Infusion of Ang-(1–7) had no effect on blood pressure or heart rate of Sprague-Dawley rats treated with the peptide. In Ang-(1–7)–treated rats, the diastolic pressures (45±9 mm Hg;n=5), systolic pressures (105±22 mm Hg; n=5), and heart rates (351±18 bpm; n=5) were unchanged compared with those of saline-infused rats (52±11 mm Hg, 97±14 mm Hg, and 382±16 bpm, respectively; n=8). Plasma concentrations of Ang-(1–7) and Ang II were measured by radioimmunoassay. Figure 1
illustrates
that 12 days of intravenous infusion of Ang-(1–7) (24
µg/kg per hour) caused a 3.5-fold increase in the circulating level
of the peptide, from 46.9±4.2 fmol/mL in saline-infused rats (n=8) to
166.0±41.2 fmol/mL in peptide-infused animals (n=6;
P<0.05). Plasma Ang II was not affected by the infusion of
Ang-(1–7).
|
Effect of Intravenous Infusion of Ang-(1–7) on
Neointimal Formation
Balloon-catheter injury of carotid arteries caused the
formation of a neointima in both saline- and
Ang-(1–7)–treated rats. Contralateral uninjured carotid arteries had
no discernible intima. Intravenous infusion of Ang-(1–7)
significantly reduced the cross-sectional area of the
neointima, as shown in Figures 2 and 3.
Ang-(1–7) caused a 37% reduction in the cross-sectional area of the
neointima, from 0.100±0.009 mm2
in saline-infused rats (n=8) to 0.063±0.011
mm2 in Ang-(1–7)–infused rats (n=6;
P<0.05). In contrast, Ang-(1–7) infusion had no effect on
the medial area of injured or uninjured carotid arteries compared with
saline-infused rats. Correspondingly, the neointima/media
ratio was reduced in Ang-(1–7)–infused rats compared with
saline-infused rats (from 0.62±0.03 in saline-infused rats to
0.42±0.07 in Ang-(1–7)–infused animals).
|
|
Effect of Intravenous Infusion of Ang-(1–7) on DNA
Synthesis in the Neointima and Media
The rate of DNA synthesis was measured by the incorporation
of BrdU into newly synthesized DNA in the neointima and the
media of injured arteries and the media of uninjured carotid arteries.
The rate of DNA synthesis was defined as the cumulative BrdU labeling
index, calculated by the percentage of nuclei within the
neointima or media incorporating BrdU during the 12-day
infusion period. BrdU was incorporated into a significant number of
cell nuclei in both the neointima (92.5±0.4%) and the
media (48.1±2.4%) of the injured carotid arteries of saline-infused
rats. Ang-(1–7) infusion significantly (P<0.05) reduced
the rate of DNA synthesis in both the neointima and the
media of the injured arteries, as shown in Figure 4. DNA synthesis was rare or absent in
the media of the uninjured carotid arteries of saline- or
Ang-(1–7)–infused rats (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Infusion of Ang-(1–7) into normotensive Sprague-Dawley rats inhibited VSMC proliferation in vivo after vascular injury. This study extends our previous work showing that Ang-(1–7) reduced both the amount of mitogen-stimulated [3H]thymidine incorporation and cell number in cultured VSMC treated in vitro with Ang-(1–7).19 DNA synthesis in both the neointima and the media of the injured artery and neointimal area were significantly reduced by Ang-(1–7) infusion compared with saline-infused rats. The increase in plasma Ang-(1–7) had no effect on blood pressure or heart rate, indicating that the antiproliferative effect of the peptide was not due to alterations in hemodynamic forces.
Ang-(1–7) inhibited the serum-, platelet-derived growth factor–, and Ang II–stimulated increase in [3H]thymidine incorporation in cultured VSMC.19 Infusion of Ang II into Sprague-Dawley rats stimulates vascular smooth muscle growth in conjunction with increased blood pressure.20 Vascular growth in response to coinfusion of Ang II and hydralazine demonstrated that the Ang II–mediated increase in proliferation was independent of its pressor effect.21 This is in agreement with a reduction in neointimal formation after vascular injury by treatment with either ACE inhibitors or AT1 receptor antagonists.23 24 25 ACE inhibitors increase circulating kinins while decreasing or having no effect on plasma Ang II, suggesting that bradykinin participates in the antiproliferative effects of ACE inhibition. Farhy et al26 showed that a B2 antagonist attenuated the ACE inhibitor–reduced neointimal formation through blockade of kinin-stimulated migration of medial cells.27 However, circulating levels of Ang-(1–7) increase 25- to 50-fold during ACE inhibition,3 4 5 secondary to increased Ang I conversion to Ang-(1–7) and inhibition of Ang-(1–7) breakdown by ACE.28 Since Ang-(1–7) inhibits vascular proliferation in vitro and in vivo, the heptapeptide may participate in the antiproliferative effects of ACE inhibition.
Ang-(1–7) reduced the cross-sectional area of the neointima and decreased the rate of DNA synthesis. In contrast, the heptapeptide decreased the rate of DNA synthesis in the media of the injured artery but did not reduce the medial cross-sectional area. The response to vascular injury in the rat carotid artery follows a pattern of medial smooth muscle proliferation, migration of smooth muscle cells across the internal elastic lamina to form the neointima, and neointimal smooth muscle proliferation.22 29 Inhibition of VSMC migration by Ang-(1–7) could account for the decreased rate of medial DNA synthesis without a significant decrease in medial area. Alternatively, Ang-(1–7) may attenuate medial VSMC apoptosis to oppose the decreased rate of medial DNA synthesis. deBlois et al30 showed that treatment of spontaneously hypertensive rats with ACE inhibitors altered vascular cell apoptosis in addition to inhibiting vascular growth.
The angiotensin receptor coupled to the inhibition of VSMC growth in vivo was not investigated in the present study. However, in cultured VSMC, we showed that inhibition of serum-stimulated [3H]thymidine incorporation by Ang-(1–7) was prevented by the sarcosine analogues of Ang II—[Sar1-Thr8]Ang II or [sarcosine1-isoleucine8]angiotensin II ([Sar1-Ile8]Ang II)—but not by AT1 or AT2 receptor antagonists.19 We identified a novel non-AT1, non-AT2 Ang-(1–7) receptor in bovine aortic endothelial cells31 and canine coronary arteries,1 suggesting that Ang-(1–7) activates a unique angiotensin peptide receptor. The Ang-(1–7)–mediated relaxation of preconstricted canine coronary arteries was prevented by sarcosine analogues of Ang II but not by AT1 or AT2 receptor antagonists.14 In addition, Iyer et al17 18 recently showed that the antihypertensive effect of combined ACE inhibition and AT1 receptor antagonism was attenuated by an antibody to Ang-(1–7), an inhibitor of Ang-(1–7) formation or [Sar1-Thr8]Ang II but not by an AT2 receptor antagonist. Collectively, these results suggest that Ang-(1–7) activates a novel Ang-(1–7) receptor to regulate blood pressure and inhibit VSMC proliferation.
Although we did not investigate the mechanisms by which Ang-(1–7) inhibits vascular proliferation, we previously showed that Ang-(1–7) released prostacyclin from cultured VSMC.7 8 9 Blockade of prostaglandin production by indomethacin attenuates the inhibition of VSMC thymidine incorporation by Ang-(1–7) (E.A. Tallant, unpublished data, 1998). Prostacyclin inhibited the growth of cultured VSMC.32 In addition, overexpression of prostacyclin synthase in rat VSMC increased prostacyclin production and decreased DNA synthesis in response to serum stimulation, providing further proof that prostacyclin inhibits VSMC growth.33 Treatment with a stable prostacyclin analogue also reduced neointimal growth in vivo after vascular injury to the rabbit aorta.34 Although other mechanisms may participate in the Ang-(1–7)–mediated inhibition of vascular growth (such as production of the growth inhibitor nitric oxide), our results suggest that Ang-(1–7) may inhibit vascular growth by the production of prostacyclin.
VSMC growth is regulated by hemodynamic, blood-borne, and tissue-derived signals to maintain normal blood flow and vessel patency.22 29 Proliferative and antiproliferative factors tend to balance VSMC growth. Artery wall thickness is maintained in normal adult arteries by permitting only a slow rate of smooth muscle cell proliferation to adjust compliance. Abnormal vascular growth is an important etiologic factor in the pathology of many vascular disorders, including hypertension. The results of the present study demonstrate that infusion of exogenous Ang-(1–7) results in a reduction in neointimal formation, suggesting that Ang-(1–7) may inhibit VSMC growth in vivo. Since plasma Ang-(1–7) is elevated after treatment with ACE inhibitors, our results suggest that Ang-(1–7) may contribute to the antiproliferative effects of ACE inhibition.
|
Acknowledgments |
|---|
This work was supported in part by grants HL-56973, HL-50066, and NS-31664 from the National Institutes of Health and a Grant-in-Aid from the North Carolina Affiliate of the American Heart Association. The authors thank Drs Patricia E. Gallagher and Ernest J. Freeman for helpful discussions and acknowledge the excellent technical assistance of Janet Hrbolich.
Received September 17, 1998; first decision October 14, 1998; accepted October 30, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1–7). Hypertension. 1997;30(pt 2):535–541.
2. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1–7) by thimet oligopeptidase (E.C.3.4.24.15) in vascular smooth muscle cells. J Vasc Biol Med. 1995;5:129–137.
3. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol. 1994;266(Regulatory Integrative Comp Physiol.):R1273–R1279.
4. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1–7) in the spontaneously hypertensive rat. Peptides. 1993;14:883–891.[Medline] [Order article via Infotrieve]
5.
Campbell DJ, Kladis A, Duncan A. Effects of converting
enzyme inhibitors on angiotensin and bradykinin
peptides. Hypertension. 1994;23:439–449.
6.
Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC,
Ferrario CM. Release of vasopressin from the rat
hypothalamo-neurohypophysial system by angiotensin-(1–7)
heptapeptide. Proc Natl Acad Sci U S A. 1988;85:4095–4098.
7.
Jaiswal N, Jaiswal RK, Tallant EA, Diz DI, Ferrario
CM. Alterations in prostaglandin production in
spontaneously hypertensive rat smooth muscle cells.
Hypertension. 1993;21:900–905.
8.
Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario
CM. Differential regulation of prostaglandin synthesis by
angiotensin peptides in porcine aortic smooth muscle cells:
subtypes of angiotensin receptors involved. J
Pharmacol Exp Ther. 1993;265:664–673.
9. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides: characterization of receptors. Hypertension. 1992;19(suppl II)II-49–II-55.
10.
Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU.
Signal transduction mechanism involved in
angiotensin-(1–7)-stimulated arachidonic
acid release and prostanoid synthesis in rabbit aortic smooth muscle
cells. J Pharmacol Exp Ther. 1998;284:388–398.
11. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1–7) in spontaneously hypertensive rats. Am J Physiol. 1995;269(Heart Circ Physiol.):H313–H319.
12.
Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL,
Winicov E, Dean RH. Angiotensin-(1–7) and nitric oxide
interaction in renovascular hypertension. Hypertension. 1995;25:796–802.
13.
Moriguchi A, Tallant EA, Matsumura K, Reilly TM, Walton
H, Ganten D, Ferrario CM. Opposing actions of
angiotensin-(1–7) and angiotensin II in the
brain of transgenic hypertensive rats. Hypertension. 1995;25:1260–1265.
14. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27(part 2):523–528.
15. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1–7). Peptides. 1993;14:679–684.[Medline] [Order article via Infotrieve]
16.
Meng W, Busija DW. Comparative effects of
angiotensin-(1–7) and angiotensin II on piglet
pial arterioles. Stroke. 1993;24:2041–2045.
17.
Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM.
Vasodepressor actions of angiotensin-(1–7) unmasked during
combined treatment with lisinopril and losartan.
Hypertension. 1998;31:699–705.
18. Iyer SN, Ferrario CM, Chappell CM. Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31(pt 2):356–361.
19.
Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA.
Angiotensin-(1–7) inhibits vascular smooth muscle cell
growth. Hypertension. 1996;28:104–108.
20.
Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM.
Angiotensin II induces smooth muscle cell proliferation in
the normal and injured rat arterial wall. Circ
Res. 1991;68:450–456.
21.
Su EJ, Lombardi DM, Siegal J, Schwartz SM.
Angiotensin induces vascular smooth muscle cell replication
independent of blood pressure. Hypertension. 1998;31:1331–1337.
22. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327–333.[Medline] [Order article via Infotrieve]
23. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 1991;139:1291–1296.[Abstract]
24.
Powell JS, Clozel J-P, Muller RKM, Kuhn H, Hefti F,
Hosang M, Baumgartner HR. Inhibitors of
angiotensin-converting enzyme prevent myointimal
proliferation after vascular injury. Science. 1989;245:186–188.
25. Strawn WB, Tallant EA, Gallagher PE, Ganten D, Ferrario CM. Reduction in neointima of transgenic (mRen-2)27 hypertensive rats by dual lisinopril/losartan administration. Am J Hypertens. 1998;11:33A. Abstract.
26. Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramapril in rat carotid artery. Biochem Biophys Res Commun. 1992;182:283–288.[Medline] [Order article via Infotrieve]
27.
Rhaleb N-E, Yang X-P, Scicli AG, Carretero OA. Role of
kinins and nitric oxide in the antihypertrophic effect of ramipril.
Hypertension. 1994;23:865–868.
28. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1–7) by angiotensin-converting enzyme. Hypertension. 1998;31(pt 2):362–367.
29. Schwartz SM, Reidy MA, de Blois D. Factors important in arterial narrowing. J Hypertens. 1997;14:S71–S81.
30. deBlois D, Tea B-S, Dam T-V, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension. 1997;29(pt 2):340–349.
31. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1–7) receptor. Hypertension. 1997;29(pt 2):388–393.
32. Uehara Y, Ishimitsu T, Kimura K, Ishii M, Ikeda T, Sugimoto T. Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats. Prostaglandins. 1988;36:847–857.[Medline] [Order article via Infotrieve]
33. Hara S, Morishita R, Tone Y, Yokoyama C, Inoue H, Kaneda Y, Ogihara T, Tanabe T. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun. 1995;216:862–867.[Medline] [Order article via Infotrieve]
34. Asada Y, Kisanuki A, Hatakeyama K, Takahama S, Koyama T, Kurozumi S, Sumiyoshi A. Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;51:245–248.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Soto-Pantoja, J. Menon, P. E. Gallagher, and E. A. Tallant Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor Mol. Cancer Ther., June 1, 2009; 8(6): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lacchini, A. S. Heimann, F. S. Evangelista, L. Cardoso, G. J. J. Silva, and J. E. Krieger Cuff-induced vascular intima thickening is influenced by titration of the Ace gene in mice Physiol Genomics, May 13, 2009; 37(3): 225 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vaz-Silva, M.M. Carneiro, M.C. Ferreira, S.V.B. Pinheiro, D.A. Silva, A.L. Silva Filho, C.A. Witz, A.M. Reis, R.A. Santos, and F.M. Reis The Vasoactive Peptide Angiotensin-(1--7), Its Receptor Mas and the Angiotensin-converting Enzyme Type 2 are Expressed in the Human Endometrium Reproductive Sciences, March 1, 2009; 16(3): 247 - 256. [Abstract] [PDF]
|
|
|
|
 |
|
 P. E. Gallagher, C. M. Ferrario, and E. A. Tallant MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1169 - C1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pignone, A. D. Rosso, K B. Brosnihan, F. Perfetto, R. Livi, G. Fiori, S. Guiducci, M. Cinelli, V. Rogai, A. Tempestini, et al. Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control Ann Rheum Dis, October 1, 2007; 66(10): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Botelho-Santos, W. O. Sampaio, T. L. Reudelhuber, M. Bader, M. J. Campagnole-Santos, and R. A. Souza dos Santos Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2485 - H2490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menon, D. R. Soto-Pantoja, M. F. Callahan, J. M. Cline, C. M. Ferrario, E. A. Tallant, and P. E. Gallagher Angiotensin-(1-7) Inhibits Growth of Human Lung Adenocarcinoma Xenografts in Nude Mice through a Reduction in Cyclooxygenase-2 Cancer Res., March 15, 2007; 67(6): 2809 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ye, J. Wysocki, J. William, M. J. Soler, I. Cokic, and D. Batlle Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3067 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ferrario Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7): An Evolving Story in Cardiovascular Regulation Hypertension, March 1, 2006; 47(3): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Gallagher, M. C. Chappell, C. M. Ferrario, and E. A. Tallant Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes Am J Physiol Cell Physiol, February 1, 2006; 290(2): C420 - C426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Raizada and S. D. Sarkissian Potential of Gene Therapy Strategy for the Treatment of Hypertension Hypertension, January 1, 2006; 47(1): 6 - 9. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ferrario, A. J. Trask, and J. A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, F. Tan, E. G. Erdos, and P. A. Deddish Hydrolysis of Angiotensin Peptides by Human Angiotensin I-Converting Enzyme and the Resensitization of B2 Kinin Receptors Hypertension, December 1, 2005; 46(6): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Tallant, C. M. Ferrario, and P. E. Gallagher Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1560 - H1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Igase, W. B. Strawn, P. E. Gallagher, R. L. Geary, and C. M. Ferrario Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1013 - H1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gurzu, M. Costuleanu, S. M. Slatineanu, A. Ciobanu, and G. Petrescu Are Multiple Angiotensin Receptor Types Involved in Angiotensin (1-7) Actions on Isolated Rat Portal Vein? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 90 - 95. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension Exp Physiol, May 1, 2005; 90(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Langeveld, W. H. van Gilst, R. A. Tio, F. Zijlstra, and A. J.M. Roks Angiotensin-(1-7) Attenuates Neointimal Formation After Stent Implantation in the Rat Hypertension, January 1, 2005; 45(1): 138 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gallagher and E.A. Tallant Inhibition of human lung cancer cell growth by angiotensin-(1-7) Carcinogenesis, November 1, 2004; 25(11): 2045 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. S. Santos, A. J. Ferreira, A. P. Nadu, A. N. G. Braga, A. P. de Almeida, M. J. Campagnole-Santos, O. Baltatu, R. Iliescu, T. L. Reudelhuber, and M. Bader Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats Physiol Genomics, May 19, 2004; 17(3): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan, and C. M. Ferrario Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors Hypertension, May 1, 2004; 43(5): 970 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Tallant and M. A. Clark Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7) Hypertension, October 1, 2003; 42(4): 574 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wiemer, L. W. Dobrucki, F. R. Louka, T. Malinski, and H. Heitsch AVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1-7) on the Endothelium Hypertension, December 1, 2002; 40(6): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ferrario Does Angiotensin-(1-7) Contribute to Cardiac Adaptation and Preservation of Endothelial Function in Heart Failure? Circulation, April 2, 2002; 105(13): 1523 - 1525. [Full Text] [PDF]
|
|
|
|
|
|
T. Mustafa, Joo Hyung Lee, Siew Yeen Chai, A. L Albiston, S. G McDowall, and F. A. Mendelsohn Bioactive angiotensin peptides: focus on angiotensin IV Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 205 - 210. [PDF]
|
|
|
|
|
|
M. A. Clark, D. I. Diz, and E. A. Tallant Angiotensin-(1-7) Downregulates the Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells Hypertension, April 1, 2001; 37(4): 1141 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Heitsch, S. Brovkovych, T. Malinski, and G. Wiemer Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells Hypertension, January 1, 2001; 37(1): 72 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Allred, D. I. Diz, C. M. Ferrario, and M. C. Chappell Pathways for angiotensin-(1---7) metabolism in pulmonary and renal tissues Am J Physiol Renal Physiol, November 1, 2000; 279(5): F841 - F850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Hansen, G. Servant, T. J. Baranski, T. Fujita, T. Iiri, and S. P. Sheikh Functional Reconstitution of the Angiotensin II Type 2 Receptor and Gi Activation Circ. Res., October 27, 2000; 87(9): 753 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Strawn, M. C. Chappell, R. H. Dean, S. Kivlighn, and C. M. Ferrario Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia Circulation, April 4, 2000; 101(13): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Kessler, T. M. Rowe, J. B. Gomos, P. M. Kessler, and G. C. Sen Physiological Non-equivalence of the Two Isoforms of Angiotensin-converting Enzyme J. Biol. Chem., August 18, 2000; 275(34): 26259 - 26264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Loot, A. J.M. Roks, R. H. Henning, R. A. Tio, A. J.H. Suurmeijer, F. Boomsma, and W. H. van Gilst Angiotensin-(1-7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats Circulation, April 2, 2002; 105(13): 1548 - 1550. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||